Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China

Figure 2

Differences in clinical characteristics and treatment between China and the United States (2012–2014). The columns successively present the percentages of ER status, PR status, and HR+/HER2+ subtype breast cancer.